A retrospective cohort study at a single children's hospital evaluated emergency sclerotherapy in 13 neonates with giant head and neck lymphatic malformations complicated by airway obstruction. The intervention involved percutaneous puncture under ultrasound guidance, placement of pigtail drainage catheters, and alternating lavage with pingyangmycin and 1% lauromacrogol. Therapeutic efficacy was evaluated 3-6 months after the final treatment based on volume reduction rate.
All 13 patients achieved resolution of respiratory symptoms and normal feeding and growth. No recurrences were reported during the follow-up period. Among patients with macrocystic lesions, all 7 achieved excellent outcomes after a single sclerotherapy course. For the 6 patients with mixed lesions, 4 achieved excellent outcomes with one course, 1 required an additional session, and 1 achieved excellent outcome after oral sirolimus was added.
Safety monitoring found transient low-grade fever in 4 cases and local swelling in 7 cases, with no severe complications reported. All adverse reactions resolved with symptomatic treatment. Key limitations include the retrospective design, single-center setting, small sample size of 13 patients, and lack of a control group. The follow-up period of 3-6 months is relatively short for assessing long-term outcomes.
While this study suggests emergency sclerotherapy may be effective for this specific neonatal emergency, clinicians should interpret these findings cautiously given the study's limitations. The approach requires specialized expertise in interventional radiology and neonatal intensive care. Further research with larger, prospective designs and longer follow-up is needed to establish the optimal management strategy for this rare condition.
View Original Abstract ↓
ObjectiveTo evaluate the efficacy and safety of emergency sclerotherapy for treating neonates with giant head and neck lymphatic malformations (LMs) complicated by airway obstruction.MethodsThis retrospective analysis included the clinical data of neonates with giant head and neck LMs complicated by airway obstruction treated at the Children's Hospital Affiliated to Shandong University from January 2020 to December 2024. All patients underwent emergency sclerotherapy under general anesthesia and real-time ultrasound guidance. After percutaneous puncture and pigtail drainage catheter placement, lesions were treated with alternating lavage with pingyangmycin and 1% lauromacrogol. Lesion volume was measured using three-dimensional (3D) volumetric MRI, and therapeutic efficacy was evaluated–3–6 months after the final treatment according to the volume reduction rate.ResultsA total of 13 neonates (8 males, 5 females) were enrolled in this study, with a mean birth weight of 3.47 ± 0.65 kg and a mean maximum lesion diameter of 9.42 ± 2.03 cm (range: 6.2–14.5 cm). There were seven cases of macrocystic LMs and six cases of mixed LMs, among which five lesions extended into the upper mediastinum and three had intralesional hemorrhage. A total of 57 sclerotherapy sessions were performed, with an average of 4.38 sessions per patient. The 3 neonates who underwent endotracheal intubation were successfully extubated 2–3 days after treatment. All patients achieved resolution of respiratory symptoms, with normal feeding and growth and no recurrence during follow-up. All 7 macrocystic LMs achieved excellent outcomes after a single sclerotherapy course. Among the six mixed LMs, four achieved excellent outcomes with one course, one required an additional sclerotherapy session, and one achieved excellent response after seven months of oral sirolimus. Transient low-grade fever (4 cases) and local swelling (7 cases) were observed as adverse reactions which resolved with symptomatic treatment, and no severe complications occurred.ConclusionEmergency sclerotherapy combined with indwelling drainage catheters is an effective and safe treatment for neonates with giant head and neck LMs complicated by airway obstruction. The alternating use of sclerosing agents, together with adjunctive sirolimus, enhances efficacy with minimal adverse reactions, offering greater therapeutic benefit than to single-agent therapy and significant clinical value.